| PHARMANOVIA |
PHARMANOVIA |
92%
|
The Company also sells SUNOSI to Distributors in Canada and on a product supply basis to Pharmanovia. |
| IGC |
IGC Pharma, Inc. |
72%
|
Reciprocal relationship from IGC graph: ing growth of the Life Sciences segment. These investments will fuel the development and delivery of innovative products that drive positive patient and custom… |
| JAZZ |
Jazz Pharmaceuticals plc |
72%
|
Reciprocal relationship from JAZZ graph: Reciprocal relationship from AXSM graph: 1,572 Segment net loss $ ( 64,542 ) $ ( 59,413 ) Reconciliation of net loss Adjustments and reconciling items — — Con… |
| JAZZ |
Jazz Pharmaceuticals plc |
72%
|
1,572 Segment net loss $ ( 64,542 ) $ ( 59,413 ) Reconciliation of net loss Adjustments and reconciling items — — Consolidated net loss $ ( 64,542 ) $ ( 59,413 ) (a) Other research and development ex… |
| LLY |
Eli Lilly and Company |
72%
|
DA issued more than 100 enforcement letters to pharmaceutical companies and compounding firms, alleging that certain promotional communications and DTC advertisements are false and misleading. Furthe… |
| LLY |
Eli Lilly and Company |
72%
|
Reciprocal relationship from LLY graph: Reciprocal relationship from AXSM graph: DA issued more than 100 enforcement letters to pharmaceutical companies and compounding firms, alleging that certain p… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
. Note 15. Acquisitions In the first quarter of 2026, the Company acquired the global rights to balipodect (AXS-20), a selective PDE10A Inhibitor for the treatment of Schizophrenia and other neuropsy… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
Reciprocal relationship from TKPHF graph: Reciprocal relationship from AXSM graph: . Note 15. Acquisitions In the first quarter of 2026, the Company acquired the global rights to balipodect (AXS-20),… |
| XENE |
Xenon Pharmaceuticals Inc. |
72%
|
Reciprocal relationship from XENE graph: Reciprocal relationship from AXSM graph: Reciprocal relationship from XENE graph: Reciprocal relationship from AXSM graph: Reciprocal relationship from XENE g… |
| AERIAL-BIOPHARMA-LLC |
AERIAL-BIOPHARMA-LLC |
62%
|
other current liabilities if payable to a third-party. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to… |
| ANTECIP-BIOVENTURES-II-LLC |
ANTECIP-BIOVENTURES-II-LLC |
62%
|
other current liabilities if payable to a third-party. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to… |
| ATNAHS-PHARMA-UK-LIMITED |
ATNAHS-PHARMA-UK-LIMITED |
62%
|
1,572 Segment net loss $ ( 64,542 ) $ ( 59,413 ) Reconciliation of net loss Adjustments and reconciling items — — Consolidated net loss $ ( 64,542 ) $ ( 59,413 ) (a) Other research and development ex… |
| BAERGIC-BIO-INC |
BAERGIC-BIO-INC |
62%
|
. Any change in our manufacturers could be costly because the commercial terms of any new arrangement could be less favorable and because the expenses relating to the transfer of necessary technology… |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
, and other miscellaneous operating costs. Research and development expenses Research and development expenses primarily include preclinical studies, clinical trials, manufacturing costs, employee-re… |
| CORNER-POST-INC |
CORNER-POST-INC |
62%
|
DA issued more than 100 enforcement letters to pharmaceutical companies and compounding firms, alleging that certain promotional communications and DTC advertisements are false and misleading. Furthe… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
s on ESG concerns may lead to new requirements that could result in increased costs associated with developing, manufacturing and distributing our products. Our ability to compete could also be affec… |
| DEUTERX-LLC |
DEUTERX-LLC |
62%
|
. Any change in our manufacturers could be costly because the commercial terms of any new arrangement could be less favorable and because the expenses relating to the transfer of necessary technology… |
| LEERINK-PARTNERS-LLC |
LEERINK-PARTNERS-LLC |
62%
|
s on ESG concerns may lead to new requirements that could result in increased costs associated with developing, manufacturing and distributing our products. Our ability to compete could also be affec… |
| SK-BIOPHARMACEUTICALS-CO-LTD |
SK-BIOPHARMACEUTICALS-CO-LTD |
62%
|
1,572 Segment net loss $ ( 64,542 ) $ ( 59,413 ) Reconciliation of net loss Adjustments and reconciling items — — Consolidated net loss $ ( 64,542 ) $ ( 59,413 ) (a) Other research and development ex… |
| XIX-BIO-LLC |
XIX-BIO-LLC |
62%
|
. Any change in our manufacturers could be costly because the commercial terms of any new arrangement could be less favorable and because the expenses relating to the transfer of necessary technology… |
